TEVA vs. GSK, TAK, ARGX, ONC, INSM, BNTX, GMAB, SMMT, ASND, and RDY
Should you be buying Teva Pharmaceutical Industries stock or one of its competitors? The main competitors of Teva Pharmaceutical Industries include GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.
Teva Pharmaceutical Industries vs. Its Competitors
Teva Pharmaceutical Industries (NYSE:TEVA) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.
Teva Pharmaceutical Industries has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.
In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than GSK. MarketBeat recorded 12 mentions for Teva Pharmaceutical Industries and 4 mentions for GSK. Teva Pharmaceutical Industries' average media sentiment score of 0.88 beat GSK's score of 0.70 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.
54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Teva Pharmaceutical Industries currently has a consensus price target of $25.57, suggesting a potential upside of 27.54%. GSK has a consensus price target of $37.38, suggesting a potential downside of 14.11%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, equities research analysts plainly believe Teva Pharmaceutical Industries is more favorable than GSK.
GSK has higher revenue and earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.
GSK has a net margin of 10.81% compared to Teva Pharmaceutical Industries' net margin of -0.95%. GSK's return on equity of 49.22% beat Teva Pharmaceutical Industries' return on equity.
Summary
GSK beats Teva Pharmaceutical Industries on 9 of the 17 factors compared between the two stocks.
Get Teva Pharmaceutical Industries News Delivered to You Automatically
Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TEVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Teva Pharmaceutical Industries Competitors List
Related Companies and Tools
This page (NYSE:TEVA) was last updated on 10/8/2025 by MarketBeat.com Staff
